Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures
Year: 2022
Type: review
Abstract: Cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment (TME) with diverse functions such as extracellular matrix (ECM) remodeling, modulation of metabolism and angiogenesis, and crosstalk with both cancer cells and infiltrating immune cells by production of growth factors, cytokines, and chemokines. Within the TME milieu, CAFs exhibit morphological and functional transitions with relatively specific markers and hold tremendous potential to facilitate tumorigenesis, development, and resistance towards multiple therapeutic strategies including chemotherapy, radiotherapy, targeted therapy, anti-angiogenesis therapy, immunotherapy, and endocrine therapy. Accordingly, CAFs themselves and the downstream effectors and/or signaling pathways are potential targets for optimizing the sensitivity of anti-cancer therapies. This review aims to provide a detailed landscape of the role that CAFs play in conferring therapeutic resistance in different cancers and the underlying mechanisms. The translational and therapeutic perspectives of CAFs in the individualized treatment of malignant tumors are also discussed.
Source: Cancer Cell International
Authors: Bing Feng, Jianzhong Wu, Bo Shen, Feng Jiang, Jifeng Feng
Institutions: Jiangsu Cancer Hospital, Nanjing Medical University
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: cancer-associated fibroblasts, tumor microenvironment, treatment resistance, chemoresistance, radiotherapy resistance, targeted therapy resistance, anti-angiogenic therapy, immunotherapy resistance, endocrine therapy resistance, extracellular matrix remodeling, cancer metabolism, angiogenesis, immune cell crosstalk, CAF heterogeneity, CAF-targeted therapy
Open Access status: gold
Estimated APC paid: $2,790
Funder: Government of Jiangsu Province
OpenAlex ID: W4225096492
